Outseer Protects $100 Billion in Payment Transactions Year-to-Date via 3-D Secure
14.9.2021 16:00:00 EEST | Business Wire | Press release
Outseer, the leader in payment authentication and monitoring solutions, has published its third quarter Fraud & Payments Report, confirming that a massive $100 billion in transactions in 2021 alone have been protected by Outseer’s 3-D secure payments authentication technology. The report also reveals continued explosive growth of worldwide 3-D Secure transactions due to skyrocketing adoption of online shopping and new PSD2 mandates. The Q3 report installment features insights from April through June of 2021 as captured through the Outseer Global Data Network, and collected while authenticating consumer transactions and investigating threats on behalf of Outseer customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005639/en/
(Graphic: Business Wire)
According to the report, 3-D Secure transactions, a global standard supported by EMVCo to authenticate digital payment transactions, have grown by an impressive 79% over the past 18 months, with Q2 year-over-year growth of 44%.
For the latest standard using EMV®3-D Secure 2.x technology specifically, the report shows a continued, steady increase across all geographies. Europe recorded the most significant jump, where 2.x transactions comprised a 46% share of all 3-D Secure transactions examined in Q2, 2021, growing nearly seven times from the 7% share reported in Q3 2020. The Americas witnessed nearly four times growth, with 2.x transaction volume jumping from a 10% share in Q3, 2020 to a 37% share in Q2, 2021.
This global share increase in 2.x transactions can be attributed to a pandemic-fueled spike in card-not-present (CNP) transactions in addition to looming Payment Services Directive (PSD2) enforcement dates. Moreover, the 2.x authentication standard from EMVCo supports consumer-friendly experiences in native mobile app environments tailed to the merchant. As the 3-D Secure standard directly supports PSD2 and Strong Customer Authentication (SCA) regulations, adoption of the 2.x version to authenticate payment transactions will increase beyond March of 2022 when PSD2 regulations go into effect across all of Europe.
“As the pandemic fuels an unprecedented spike in digital shopping globally, we’re excited to see card issuers and merchants embrace the gold standard of payment authentication technology,” said Armen Najarian, CMO and Chief Identity Officer at Outseer. “The latest 3-D Secure standard delivers the shopping experiences consumer demand, with the positive economics and growth that card issuers and merchants require. We expect the global payments ecosystem to deepen its use of 3-D Secure to authenticate digital transactions.”
Other notable insights from the Q3 Outseer Fraud & Payments Report include:
- Over 49,000 attacks detected by the Outseer Anti-Fraud Command Center in Q2 2021 alone
- Brand Abuse attacks continue to be the most dominant attack vector for the third consecutive quarter, comprising 49% of all attack types
- 70% of fraudulent transactions in digital banking originated through the mobile channel, with the biggest rise seen in mobile app fraud
- The presence of Rogue Mobile Apps increased 66% from last quarter and 140% year-over-year. Fraudsters are creating fake banking apps and uploading them to various app stores to infect consumers’ devices with malware and harvest user credentials for account takeover activities
- Outseer recovered over 4.5 million unique compromised cards and card previews from online card stores and fraud communication channels in Q2 2021
Download the Q3, 2021 Outseer Fraud & Payments Report here: https://www.outseer.com/fraud-report-q3-2021/
About Outseer
Outseer, an RSA Company, empowers the digital economy to grow by authenticating billions of transactions annually. Our payment and account monitoring solutions increase revenue and reduce customer friction for card issuing banks, payment processors, and merchants worldwide. Leveraging 20 billion annual transactions from 6,000 global institutions contributing to the Outseer Data Network, our identity-based science delivers the highest fraud detection rates and lowest customer intervention in the industry. See what others can’t at outseer.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005639/en/
Contact information
David Pedersen
David.Pedersen@outseer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom